Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ITR-251 is a potent and selective inhibitor of Monoamine Oxidase A (MAO-A) with reversible inhibition and limited capacity for blood brain barrier (BBB) crossing. Four dose levels will be tested. Dose could be also reduced to dose level -1.”In the company’s words, NCT07870096 on ClinicalTrials.gov
- Tested for
- Solid Tumor Cancer, Castration Resistant Metastatic Prostate Cancer
- Main trialPhase 1
- “This is an open-label, Phase I/Ib trial including an initial dose-escalation phase in patients with advanced solid tumors and a dose-expansion phase at recommended phase 2 dose (RP2D) in combination with Androgen Receptor Pathway Inhibitors (ARPi) in patients with metastatic castration resistant prostate cancer (mCRPC). The trial will enroll following a 3+3 design up to 6 patients with any type of solid tumors after progression to standard treatments at each dose level during the dose-escalation phase. Four dose levels are planned. If the first DL is deemed not safe, the next patients could…”In the company’s words, NCT07870096 on ClinicalTrials.gov
Other drugs for Solid Tumor Cancer
- BCD-217Biocad · Phase 3
- ProlgolimabBiocad · Phase 3
- BalstilimabAgenus Inc. · Phase 2
- BotensilimabAgenus Inc. · Phase 2
- SYS6088CSPC · Phase 1/2
- GB268Eddingpharm (Zhuhai) Co., Ltd. · Phase 1/2
Coming up1
- Jul 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Jul 2029 | ITR-251 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026